Cell MedX Corp. (CMXC) Provides Corporate Update

LAS VEGAS, NV--(Marketwired - Jul 13, 2016) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to provide its shareholders with an update on its observational clinical trial carried out by Nutrasource Diagnostics Inc. ("NDI") as well as its research and development of the eBalance Devices.

Further to the news release the Company issued on January 11, 2016, during February and March the Company has received an additional 25 eBalance Professional Series (Pro) devices in anticipation of supplying approved clinical sites for investigational purposes when authorized by regulatory bodies.

As of the date of this corporate update the Company, with the assistance of NDI, has secured the main research facility in Hamilton, Ontario. An investigational protocol has been completed as well as Informed Consent and Ethics Board submission documentation. Thus, preparing Cell MedX to enter regulated clinical trials. All clinical trials will be posted on clinicaltrials.gov upon approval of government regulatory agencies detailing the project protocol, sites and progress.

Cell MedX President and CEO, Mr. Frank McEnulty, commented: "We are very pleased to see our observational clinical trial in Canada progressing as scheduled, and look forward to initiating our first patient in the third calendar quarter of 2016."

About Cell MedX Corp (OTCQB: CMXC)

Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage both the illness and related complications. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company's weekly newsletter, please go to www.cellmedx.com/media/newsletters/

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance Technology is still in development. The Company does not currently have any commercially marketable products based on the eBalance Technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.